Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aminolevulinic acid - DUSA

Next Previous
Drug Profile

Aminolevulinic acid - DUSA

Alternative Names: 5 ALA; 5-Aminolaevulinic acid; 5-Aminolevulinic acid; ALA - DUSA; aminolevulinic acid HCL - DUSA; Delta-aminolevulinic acid; Levulan PDT; Levulan photodynamic therapy; Levulan/Kerastick; Levulan™

Latest Information Update: 31 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PARTEQ Innovations
  • Developer Cleveland Clinic; DUSA Pharmaceuticals
  • Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal dysplasia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • Phase II Brain cancer; Skin cancer
  • No development reported Barrett's oesophagus; Basal cell nevus syndrome
  • Discontinued Acne vulgaris; Leucoplakia; Oesophageal cancer; Photodamage; Psoriasis

Most Recent Events

  • 27 Jul 2026 Sun Pharmaceutical Industries plans a phase I trial for Actinic keratosis in USA (Topical) in August 2026 (NCT07729579)
  • 29 Nov 2025 Sun Pharmaceutical Industries initiates enrolment in a phase-III trial for Actinic keratosis in USA (Topical) (NCT07144852)
  • 19 Nov 2025 Sun Pharmaceutical Industries initiates enrolment in a phase-III trial for Actinic keratosis in USA (Topical) (NCT07144345)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top